Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate (BIODYMF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02883439
Recruitment Status : Withdrawn (no available patients)
First Posted : August 30, 2016
Last Update Posted : July 13, 2021
Sponsor:
Collaborators:
MEDA Pharma GmbH & Co. KG
University of Wuerzburg
Information provided by (Responsible Party):
University Hospital, Ghent

Brief Summary:
The aim of this study is to investigate and to compare the bioavailability of MP29-02 and fluticasone propionate in nasal tissue after nasal application. This may provide a rational basis for the use of 1 puff per nostril dosage regimen of the drugs. Clinical experience has demonstrated the efficacy of the twice-daily treatment; however, so far, no data are available on the local tissue concentrations of MP29-02 after topical application.

Condition or disease Intervention/treatment Phase
Bioavailability Study Drug: MP29-02 Drug: Fluticasone propionate Not Applicable

Detailed Description:

The study will be a single-centre, two-treatment half-side comparative open-label trial; all subjects will receive Dymista® or Flixonase Aqua in one nostril each.

Nasal tissue samples will be obtained from 24 patients. Subjects will be selected based on the subjects plan to undergo septoplasty, septorhinoplasty, or functional endoscopic sinus surgery. Subjects with different diagnoses can be added in the study: non-allergic rhinitis, allergic rhinits, chronic sinusitis and nasal polyposis. The number of subjects is based on a previous experiment where the presence of fluticasone propionate was tested on human nasal mucosal surface and in human nasal tissue after nasal application (Bonsmann, 2001).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Open Label Two -Treatment Half Side Comparative Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasoen Propionate
Actual Study Start Date : August 2016
Actual Primary Completion Date : March 2020
Actual Study Completion Date : March 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Investigational product
MP29-02 137
Drug: MP29-02
local nasal application
Other Name: Dymista

Active Comparator: Non-investigational product
fluticasone propionate
Drug: Fluticasone propionate
local nasal application
Other Name: FP




Primary Outcome Measures :
  1. bioavailability of MP29-02 in human nasal mucosa compared to commercially available fluticasone propionate [ Time Frame: 1 hour ]
    bioavailability of both medicines will be tested in nasal mucosa and nasal secretion 1 after application



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • - Male and female patients
  • Age: 18 - 70 years (included)
  • Subjects who need to undergo septoplasty, septorhinoplasty or functional endoscopic sinus surgery unrelated to this study
  • Willing and able to provide informed consent

Exclusion Criteria:

  • - Patients who are member of the staff or relatives thereof directly involved in the conduct of the protocol
  • Participant in any other trial during the last 30 days
  • Previous treatment with Dymista or any other topical corticosteroid spray or drops within the last month before the operation
  • Previous treatment with systemic corticosteroid in the last 2 months before operation
  • Previous treatment with anti-histaminics 7 days before operation
  • Pregnant or breast feeding women
  • Allergic for one of the compounds azelastinehydrochloride or fluticasonpropionate
  • Significant co-morbidity (for instance, but not limited to):

    • Glaucoma, cataracts, and increased intraocular pressure.
    • Subjects with active or quiescent tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex
    • Subjects with severe liver disease
  • Use of prohibited concomitant medication

    • Potent inhibitors of cytochrome P450 (CYP) 3A4
    • Ritonavir
  • Patients unwilling or unable to attend the proposed visit schedule
  • Patients suspected or known not to be trustworthy or who are likely not to comply with the study directives

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02883439


Locations
Layout table for location information
Belgium
University Hospital Ghent, departement otorhinolaryngology
Ghent, Belgium, 9000
Sponsors and Collaborators
University Hospital, Ghent
MEDA Pharma GmbH & Co. KG
University of Wuerzburg
Investigators
Layout table for investigator information
Principal Investigator: Claus Bachert Upper Airways Research Laboratory, Department of Oto-Rhino-Laryngology, Ghent University Hospital, Ghent, Belgium.
Layout table for additonal information
Responsible Party: University Hospital, Ghent
ClinicalTrials.gov Identifier: NCT02883439    
Other Study ID Numbers: 2015-002865-40
First Posted: August 30, 2016    Key Record Dates
Last Update Posted: July 13, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by University Hospital, Ghent:
MP29-02
Additional relevant MeSH terms:
Layout table for MeSH terms
Fluticasone
Xhance
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents